SCHEMBL3016410

SCHEMBL3016410

O=S(=O)(c1c(F)c(F)c(F)c(F)c1F)C1CCN(c2nc(Cc3ccc(F)c(F)c3)cs2)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1G O43497 2/20 0.37
CACNA1H O95180 2/20 0.37
CACNA1I Q9P0X4 2/20 0.37
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
HRH3 Q9Y5N1 1/20 0.34
RIPK1 Q13546 1/20 0.33
DNM1L O00429 4/20 0.33
AR P10275 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
DRD4 P21917 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
AOC3 Q16853 1/20 0.32
HDAC1 Q13547 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015392 0.91 PROKR1 (0.36) CACNA1GCACNA1HCACNA1INPC1RAB9A
SCHEMBL3017002 0.91 MAPT (0.35) CACNA1GCACNA1HCACNA1INPC1RAB9A
SCHEMBL3022973 0.91 AR (0.39) CACNA1GCACNA1HCACNA1INPC1RAB9A
SCHEMBL3015850 0.89 MAPT (0.39) NPC1RAB9ASMN1; SMN2HRH3L3MBTL1
SCHEMBL3007844 0.89 CACNA1G (0.36) CACNA1GCACNA1HCACNA1INPC1RAB9A
SCHEMBL3008623 0.89 CACNA1G (0.36) CACNA1GCACNA1HCACNA1INPC1RAB9A
SCHEMBL3020062 0.88 L3MBTL1 (0.37) NPC1RAB9ASMN1; SMN2HRH3AR
SCHEMBL3012509 0.88 DNM1L (0.34) NPC1RAB9ASMN1; SMN2HRH3DNM1L
SCHEMBL3008790 0.88 CACNA1G (0.33) CACNA1GCACNA1HCACNA1INPC1RAB9A
SCHEMBL3013010 0.88 MAPT (0.33) NPC1RAB9ASMN1; SMN2HRH3DNM1L

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CACNA1G 3093/4885CACNA1H 3804/4885CACNA1I 2345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.